edoc

The Equatoguinean Malaria Vaccine Initiative: from the launching of a clinical research platform to malaria elimination planning in Central West Africa

Billingsley, Peter F. and Maas, Carl D. and Olotu, Ally and Schwabe, Christopher and García, Guillermo A. and Rivas, Matilde Riloha and Hergott, Dianna E. B. and Daubenberger, Claudia and Saverino, Elizabeth and Chaouch, Adel and Embon, Oscar and Chemba, Mwajuma and Nyakarungu, Elizabeth and Hamad, Ali and Cortes, Carlos and Schindler, Tobias and Mpina, Maximillian and Mtoro, Ali and Sim, B. Kim Lee and Richie, Thomas L. and McGhee, Ken and Tanner, Marcel and Obiang Lima, Gabriel Mbaga and Abdulla, Salim and Hoffman, Stephen L. and Ayekaba, Mitoha Ondo'o. (2020) The Equatoguinean Malaria Vaccine Initiative: from the launching of a clinical research platform to malaria elimination planning in Central West Africa. American Journal of Tropical Medicine and Hygiene, 103 (3). pp. 947-954.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/82054/

Downloads: Statistics Overview

Abstract

Fifteen years of investment in malaria control on Bioko Island, Equatorial Guinea (EG), dramatically reduced malaria-associated morbidity and mortality, but the impact has plateaued. To progress toward elimination, EG is investing in the development of a malaria vaccine. We assessed the unique public-private partnership that has had such a significant impact on malaria on Bioko Island and now added a major effort on malaria vaccine development. As part of a $79M commitment, the EG government (75%) and three American energy companies (25%) have invested since 2012 greater than $55M in the Equatoguinean Malaria Vaccine Initiative (EGMVI) to support clinical development of Sanaria; ®; PfSPZ vaccines (Sanaria Inc., Rockville, MD). In turn, the vaccine development program is building human capital and physical capacity. The EGMVI established regulatory and ethical oversight to ensure compliance with the International Conference on Harmonization and Good Clinical Practices for the first importation of investigational product, ethical approval, and conduct of a clinical trial in Equatoguinean history. The EGMVI has completed three vaccine trials in EG, two vaccine trials in Tanzania, and a malaria incidence study, and initiated preparations for a 2,100-volunteer clinical trial. Personnel are training for advanced degrees abroad and have been trained in Good Clinical Practices and protocol-specific methods. A new facility has established the foundation for a national research institute. Biomedical research and development within this visionary, ambitious public-private partnership is fostering major improvements in EG. The EGMVI plans to use a PfSPZ Vaccine alongside standard malaria control interventions to eliminate Pf malaria from Bioko, becoming a potential model for elimination campaigns elsewhere.
Faculties and Departments:03 Faculty of Medicine > Departement Public Health > Sozial- und Präventivmedizin > Malaria Vaccines (Tanner)
09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Epidemiology and Public Health (EPH) > Health Interventions > Malaria Vaccines (Tanner)
09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH)
09 Associated Institutions > Swiss Tropical and Public Health Institute (Swiss TPH) > Department of Medical Parasitology and Infection Biology (MPI) > Clinical Immunology (Daubenberger)
UniBasel Contributors:Schindler, Tobias and Mpina, Maximillian and Tanner, Marcel and Daubenberger, Claudia
Item Type:Article, refereed
Article Subtype:Research Article
Publisher:American Society of Tropical Medicine and Hygiene
ISSN:0002-9637
e-ISSN:1476-1645
Note:Publication type according to Uni Basel Research Database: Journal article
Related URLs:
Identification Number:
Last Modified:12 Apr 2021 10:02
Deposited On:12 Apr 2021 10:02

Repository Staff Only: item control page